A Study of the Efficacy and Safety of Pregabalin for the Treatment of Diabetic Peripheral Neuropathy or Postherpetic Neuralgia
Efficacy and Safety of Pregabalin in an Open-label, Non-comparative, Flexible-dose Trial With Diabetic Peripheral Neuropathy or Postherpetic Neuralgia
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Aachen, Germany, 52064
- Pfizer Investigational Site
-
Albstadt, Germany, 72458
- Pfizer Investigational Site
-
Berlin, Germany, 10117
- Pfizer Investigational Site
-
Berlin, Germany, 13053
- Pfizer Investigational Site
-
Berlin, Germany, 10435
- Pfizer Investigational Site
-
Bielefeld, Germany, 33604
- Pfizer Investigational Site
-
Celle, Germany, 29221
- Pfizer Investigational Site
-
Deggingen, Germany, 73326
- Pfizer Investigational Site
-
Duisburg, Germany, 47051
- Pfizer Investigational Site
-
Erbach, Germany, 64711
- Pfizer Investigational Site
-
Erfurt, Germany, 99089
- Pfizer Investigational Site
-
Frankfurt, Germany, 60311
- Pfizer Investigational Site
-
Gera, Germany, 07548
- Pfizer Investigational Site
-
Goeppingen, Germany, 73033
- Pfizer Investigational Site
-
Hamburg, Germany, 21073
- Pfizer Investigational Site
-
Hamburg, Germany, 22149
- Pfizer Investigational Site
-
Hamburg, Germany, 22607
- Pfizer Investigational Site
-
Hemsbach, Germany, 69502
- Pfizer Investigational Site
-
Hildesheim, Germany, 31134
- Pfizer Investigational Site
-
Holle, Germany, 31188
- Pfizer Investigational Site
-
Itzehoe, Germany, 25524
- Pfizer Investigational Site
-
Karlsruhe, Germany, 76199
- Pfizer Investigational Site
-
Karlsruhe, Germany, 76133
- Pfizer Investigational Site
-
Katzhuette, Germany, 98746
- Pfizer Investigational Site
-
Leer, Germany, 26789
- Pfizer Investigational Site
-
Leipzig, Germany, 04103
- Pfizer Investigational Site
-
Limburgerhof, Germany, 67117
- Pfizer Investigational Site
-
Ludwigshafen, Germany, 67069
- Pfizer Investigational Site
-
Ludwigshafen, Germany, 67061
- Pfizer Investigational Site
-
Luebeck, Germany, 23552
- Pfizer Investigational Site
-
Luenen, Germany, 44534
- Pfizer Investigational Site
-
Mainz, Germany, 55116
- Pfizer Investigational Site
-
Marl, Germany, 45768
- Pfizer Investigational Site
-
Muenchen, Germany, 81479
- Pfizer Investigational Site
-
Muenster, Germany, 48129
- Pfizer Investigational Site
-
Osnabrueck, Germany, 49078
- Pfizer Investigational Site
-
Recklinghausen, Germany, 45657
- Pfizer Investigational Site
-
Senftenberg, Germany, 01968
- Pfizer Investigational Site
-
Sinsheim, Germany, 74889
- Pfizer Investigational Site
-
Surwold, Germany, 26903
- Pfizer Investigational Site
-
Unterhaching, Germany, 82008
- Pfizer Investigational Site
-
Veitsbronn, Germany, 90587
- Pfizer Investigational Site
-
Weimar, Germany, 99425
- Pfizer Investigational Site
-
Wiesbaden, Germany, 65191
- Pfizer Investigational Site
-
Witten, Germany, 58452
- Pfizer Investigational Site
-
Zwoenitz, Germany, 08297
- Pfizer Investigational Site
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion criteria:
- Diagnosis of DPN or PHN
- Score on the Numeric Rating Scale of at least 4/10
Exclusion Criteria:
- Hospitalized patients
- Neurologic disorders unrelated to DPN or PHN or any severe pain that may confound the assessment of DPN- or PHN-related pain
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: 1
|
Pregabalin capsules; initial dose of 75 mg twice daily for 4 days.
Dose could be increased based on individual patient's response and tolerability to 150 mg twice daily from Day 4 onwards, with a further increase to 300 mg twice daily from Day 14 onwards if needed.
Total duration of treatment was 28 days.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Correlation between global status (as measured by the Clinical Global Impression of Change [CGIC] and the Patient Global Impression of Change [PGIC]) and changes in pain, anxiety, and sleep parameters
Time Frame: Baseline to Week 4
|
Baseline to Week 4
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Mean sleep score from patient's daily sleep interference diary
Time Frame: 14 and 7 days before baseline, baseline, and Days 4, 7, 14, and 28
|
14 and 7 days before baseline, baseline, and Days 4, 7, 14, and 28
|
|
Change from baseline in mean sleep score from patient's daily sleep interference diary
Time Frame: End of treatment
|
End of treatment
|
|
Mean anxiety score from patient's daily anxiety diary
Time Frame: 14 and 7 days before baseline, baseline, and Days 4, 7, 14, and 28
|
14 and 7 days before baseline, baseline, and Days 4, 7, 14, and 28
|
|
Adverse events
Time Frame: 14 and 7 days before baseline, baseline, and Days 4, 7, 14, and 28
|
14 and 7 days before baseline, baseline, and Days 4, 7, 14, and 28
|
|
Change from baseline in Pain Treatment Satisfaction Scale (PTSS) 9 items score
Time Frame: End of treatment
|
End of treatment
|
|
Median time to pain response profile
Time Frame: Over the first week
|
Over the first week
|
|
CGIC and PGIC
Time Frame: End of treatment
|
End of treatment
|
|
Change from baseline in EuroQOL (as measures by EQ-5D)
Time Frame: End of treatment
|
End of treatment
|
|
Change from baseline in mean anxiety score from patient's daily anxiety diary
Time Frame: End of treatment
|
End of treatment
|
|
Change from baseline in Medical Outcomes Study (MOS)-Sleep Scale score
Time Frame: End of treatment
|
End of treatment
|
|
Course of mean pain score of patient's daily pain diary (NRS)
Time Frame: Throughout the study
|
Throughout the study
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Start
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Nervous System Diseases
- Pain
- Neurologic Manifestations
- Endocrine System Diseases
- Diabetes Complications
- Diabetes Mellitus
- Neuromuscular Diseases
- Neuralgia
- Peripheral Nervous System Diseases
- Diabetic Neuropathies
- Neuralgia, Postherpetic
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Central Nervous System Depressants
- Peripheral Nervous System Agents
- Analgesics
- Sensory System Agents
- Tranquilizing Agents
- Psychotropic Drugs
- Membrane Transport Modulators
- Anti-Anxiety Agents
- Anticonvulsants
- Calcium-Regulating Hormones and Agents
- Calcium Channel Blockers
- Pregabalin
Other Study ID Numbers
Other Study ID Numbers
- A0081031
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.